flâneur

Overview of the treatment of renal cell carcinoma - UpToDate

uptodate.com · 360 words · saved by 1 readers

In patients with localized clear cell renal cell carcinoma (RCC) treated with nephrectomy, adjuvant immunotherapy is an established treatment option, but long-term data on overall survival (OS) were previously limited. In extended follow-up of a randomized trial in approximately 1000 patients with clear cell RCC treated with nephrectomy, one year of adjuvant pembrolizumab improved four-year OS compared with placebo (91 versus 86 percent) [1]. For patients with clear cell RCC at intermediate-high or high risk of disease recurrence following nephrectomy, we recommend adjuvant pembrolizumab. (See "Overview of the treatment of renal cell carcinoma", section on 'Approach to adjuvant therapy'.) Read more INTRODUCTION Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tum

Overview of the treatment of renal cell carcinoma INTRODUCTION Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary kidney neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and kidney sarcomas, are rare. Nephroblastoma (Wilms tumor) is common in children (5 to 6 percent of pediatric malignancies). (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma" and…

related reading